Molecular clues and new therapies for myelofibrosis and related blood cancers
Official title: Project 1: Molecular Pathogenesis and Therapy of Myelofibrosis
Funded at Icahn School of Medicine at Mount Sinai · NIH-11399012 · Data updated 2026-11-12
This grant supports research to understand what drives myelofibrosis and related disorders and to develop new treatment ideas for patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 1, 2006 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $453,221 |
| NIH project number | 5P01CA108671-18 |
| Project ID | NIH-11399012 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with primary myelofibrosis or myeloproliferative neoplasms at risk of progression
✕Less likely to help
Patients without disease progression risk or those not eligible for future targeted therapies may see limited direct benefit
What this research studies
Researchers at Icahn School of Medicine at Mount Sinai will study how genetic changes and inflammatory signals contribute to myelofibrosis and the progression of related conditions. The work focuses on JAK-STAT signaling and newly identified epigenetic and inflammatory pathways that may worsen disease and treatment resistance. By combining laboratory studies with patient data, the team aims to identify targets for therapies beyond current JAK2 inhibitors. The goal is to translate these findings into strategies that prevent progression and improve symptoms for people with myeloproliferative neoplasms.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that slow or stop disease progression and relieve symptoms for patients with myelofibrosis and related disorders.
How similar studies have gone: Similar research has identified JAK-STAT signaling and epigenetic pathways as important in MF, with ongoing development of new therapies in early stages
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Levine, Ross L — Icahn School of Medicine at Mount Sinai
- Study coordinator: Levine, Ross L
Related research
Other NIH-funded projects on the same topics.
-
Strategies to deplete myelofibrosis stem cells using HDM2/p53 pathway
A patient-focused program tests a therapy that may selectively reduce disease-causing blood stem cells in people with myelofibrosis.
-
Megakaryocyte changes in myelofibrosis and its progression to leukemia
A scientist-guided project will study how abnormal megakaryocytes and signals like TGF-β and IL-13 may drive progression from myelofibrosis toward acute leukemia, with potential implications for future treatments.
-
Myelofibrosis and the bone marrow environment: how inflammation changes blood production
A doctor-researcher is studying how inflammation in the bone marrow affects the blood-forming system in people with myeloproliferative neoplasms (MPNs) to find ways to prevent scarring and leukemia.
-
Early detection of treatment response in myelofibrosis using a new imaging technology
A new, quick imaging method could tell patients with myelofibrosis early whether a treatment is working.
-
MYC-driven vulnerability in myelofibrosis could guide new therapies
A new project is exploring how the MYC protein contributes to myelofibrosis and whether it can be targeted to help people with this blood cancer.
-
MRI markers to monitor bone marrow in myelofibrosis
Advanced MRI scans will be used to see bone marrow changes in people with myelofibrosis so doctors can tell sooner whether new targeted drugs are working.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.